Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP2 | Q6P179 | 3/20 | 0.50 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.50 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.50 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.43 |
| ▸ | NPY4R | P50391 | 3/20 | 0.42 |
| ▸ | NPY1R | P25929 | 2/20 | 0.42 |
| ▸ | NPY2R | P49146 | 2/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.42 |
| ▸ | NMT2 | O60551 | 1/20 | 0.41 |
| ▸ | NMT1 | P30419 | 1/20 | 0.41 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | GSR | P00390 | 1/20 | 0.40 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.39 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.39 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.39 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30436626 | 0.94 | NPY4R (0.48) | ERAP2ERAP1LNPEPNPY4RNPY1R | |
| SCHEMBL30509914 | 0.94 | NPY4R (0.48) | ERAP2ERAP1LNPEPNPY4RNPY1R | |
| SCHEMBL30984669 | 0.92 | NPY4R (0.48) | ERAP2ERAP1LNPEPNPY4RNPY1R | |
| SCHEMBL29414886 | 0.90 | NMT1 (0.51) | ERAP2ERAP1LNPEPNPY4RNPY1R | |
| SCHEMBL29399781 | 0.88 | NMT1 (0.52) | ERAP2ERAP1LNPEPNPY4RNPY1R | |
| SCHEMBL31528144 | 0.88 | PTPN1 (0.46) | ERAP2ERAP1LNPEPNPY4RNPY1R | |
| SCHEMBL26627203 | 0.88 | NMT1 (0.52) | ERAP2ERAP1LNPEPNPY4RNPY1R | |
| SCHEMBL29714923 | 0.88 | ERAP2 (0.58) | ERAP2ERAP1LNPEPNOD1CPB2 | |
| SCHEMBL10928123 | 0.88 | ERAP2 (0.58) | ERAP2ERAP1LNPEPNOD1CPB2 | |
| SCHEMBL1711266 | 0.88 | ERAP2 (0.58) | ERAP2ERAP1LNPEPNOD1CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025058511-A1 | ACYLTRANSFERASE-CATALYSED MODIFICATION OF PEPTIDES | ENDOPROTEASE SERVICES B.V. (NL) | 2025-03-20 | — | — | WO | disclosed |
| US-20070010543-A1 | Compositions and methods for treating gastrointestinal hypomotility and associated disorders | DYNOGEN PHARMACEUTICALS, INC. (US) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010543-A1 | Compositions and methods for treating gastrointestinal hypomotility and associated disorders | HTR3A, HNMT, HTR3B | ERAP2 2912/4885ERAP1 3836/4885LNPEP 2374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.